GlassScriptPhysician profile
Steffi D Lena
NPI 1942676457
$2,700.70
in general payments reported to CMS, 2019-2025
13 companies · $872 in 2025
The $872 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2022: $12.87 · 2023: $468 · 2024: $1,226 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,320 · Education: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,319.52 |
| Education | $245.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $953.22 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $627.84 | 2023-2025 | Tezspire, Fasenra, Airsupra |
| Inspire Medical Systems, INC. | $318.86 | 2023-2025 | Inspire |
| Philips North America LLC | $228.73 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Regeneron Healthcare Solutions, INC. | $145.82 | 2023-2024 | Dupixent |
| Ambu INC. | $117.87 | 2023 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Amgen INC. | $77.43 | 2024 | Tezspire |
| Genzyme Corporation | $63.61 | 2023-2025 | |
| Baxter Healthcare | $20.96 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $16.62 | 2024 | Aralast |
| Paratek Pharmaceuticals, INC. | $16.23 | 2023 | Nuzyra |
| Insmed, INC. | $13.56 | 2025 | Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steffi Lena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.